Literature DB >> 12174076

Survival of grafts in coup de sabre.

Sung-Wook Park1, Han-Young Wang.   

Abstract

BACKGROUND: Treatment of coup de sabre must remain conservative until the disease is no longer in an active state. When activity has ceased, some operative intervention is safe and effective for the correction of deformity. While hair transplantation showed high survival rates for the correction of cicatricial alopecia, it has not yet been reported to be performed for the correction of coup de sabre.
OBJECTIVE: To examine the therapeutic possibility of hair transplantation for the correction of coup de sabre.
METHODS: Follicular units consisting of two to three hairs from the patient's occipital scalp were transplanted using Choi hair transplanters.
RESULTS: Ten-month follow-up studies showed an 86.5% survival rate and 10-14 cm (mean 12 cm) length of the transplanted hairs.
CONCLUSION: When coup de sabre is no longer in an active state, hair transplantation is a useful method for cosmetic improvement of the alopecia.

Entities:  

Mesh:

Year:  2002        PMID: 12174076     DOI: 10.1046/j.1524-4725.2002.02021.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  4 in total

1.  [Surgical correction of scleroderma en coup de sabre].

Authors:  T Dirschka; J Jackowski; E Bierhoff; R Fölster-Holst
Journal:  Hautarzt       Date:  2007-07       Impact factor: 0.751

Review 2.  A Systematic Review of the Outcome of Hair Transplantation in Primary Scarring Alopecia.

Authors:  Chloe Ekelem; Christine Pham; Natasha Atanaskova Mesinkovska
Journal:  Skin Appendage Disord       Date:  2018-09-05

3.  Surgical Management of Localized Scleroderma.

Authors:  Jae Hyun Lee; Soo Yeon Lim; Jang Hyun Lee; Hee Chang Ahn
Journal:  Arch Craniofac Surg       Date:  2017-09-26

4.  A surgical approach to linear scleroderma using Medpor and dermal fat graft.

Authors:  Keun Tae Kim; Hook Sun; Eui Han Chung
Journal:  Arch Craniofac Surg       Date:  2018-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.